<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82537">
  <stage>Registered</stage>
  <submitdate>16/01/2008</submitdate>
  <approvaldate>23/01/2008</approvaldate>
  <actrnumber>ACTRN12608000039381</actrnumber>
  <trial_identification>
    <studytitle>An open label cross-over study of direct transfers between methadone and buprenorphine maintenance</studytitle>
    <scientifictitle>An open label cross-over study of the effect of direct transfers between methadone and buprenorphine maintenance on sleep, cognitive, endocrine and cardio-respiratory function.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Heroin dependence</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Thirty opioid maintenance patients who are seeking to switch between methadone and buprenorphine/naloxone will be tested pre and post transfer on a range of clinical outcomes including sleep function, cognitive function, endocrine function, cardio-respiratory function and driving performance. Methadone is a full opioid agonist with a usual daily maintainence dose of 30-80 mg taken orally.  Buprenorphine is a partial opioid agonist  taken sublingually up to a maximum of 32 mg.  Doses vary according to individual.  The duration of the study follow up is 3 months.</interventions>
    <comparator>Within subjects design.  Subjects act as their own control.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Range of domains and instruments.For cognitive testing we will be using the Coninuous Performace test, the Stroop Clor-Word Test, Trail Making Tests, Letter Numbering and Digital span.   Sllep functionng will be test under laboratory conditions with polysomnography, blood topxiocology, cardiovascular and respiratory responses to hypoxia and hypercapnia.  Driving performance will be tested on a motor vehicle simulator.  Endcocrine function will be examined through self-rated questionnaires and plasma hormone evels.</outcome>
      <timepoint>One month pre transfer, one month post transfer with final 3 month follow up</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Craving, retention, substance use and with drawal.  Self rated scales.</outcome>
      <timepoint>One month pre transfer, one month post transfer with final 3 month follow up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable methadone or buprenorphine treatment &gt; 2 months, seeking to transfer to an alteernate opioid maintenance.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Active or uncontrolled severe psychiatric illness or medical problems.  No other current drug dependence or withdrawal iisues.  Pregnancy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/03/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Langton Centre</primarysponsorname>
    <primarysponsoraddress>591 South Dowling Street
Surry Hills NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Reckitt Benckiser</fundingname>
      <fundingaddress>West Ryde</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal Prince Alfred Hospital</sponsorname>
      <sponsoraddress>Drug and Alcohol Services
Missenden Road
Camperdown NSW 2042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This project is designed to examine whether opiate subsititution on table doses of methadone or buprenorphine differentiall affect clinical outcomes (i.e. drug use), cognitive function (i.e. attention), endocirne function (i.e. libido), cardio-respiratory function (i.e. heart rate), sleep function (sleep activity) and driving skills.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>1/12/2007</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nick Lintzeris</name>
      <address>Alcohol and Drug Services
Royal Prince Alfred Hospital
Camperdown NSW 2042</address>
      <phone>02 9332 8777</phone>
      <fax />
      <email>nicholas.lintzeris@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>James Shearer</name>
      <address>Langton Centre
591 South Dowling Street
Surry Hills NSW 2010</address>
      <phone>02 9332 8777</phone>
      <fax />
      <email>james.shearer@sesiahs.health.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>